Abstract
Heart failure is characterized by elevated circulating catecholamine levels and extensive abnormalities in β-adrenergic receptor signaling. Under physiological conditions, sympathetic modulation via catecholamines induces positive inotropic, chronotropic and lusitropic responses. Well established in heart failure patients is a pronounced activation of the sympathetic system, accompanied by downregulation and desensitization of β-adrenergic receptors, leading to a markedly diminished β-adrenergic contractile response. In this review, we will discuss the normal β-adrenergic receptor signaling pathway in the heart and focus on the pathphysiological alterations of β-adrenergic receptor signaling and contractile proteins in heart failure.
Keywords: Heart failure, β adrenergic receptors, myofilament proteins, cardiomyocytes
Current Pharmaceutical Biotechnology
Title:Alteration of the Beta-Adrenergic Signaling Pathway in Human Heart Failure
Volume: 13 Issue: 13
Author(s): Nazha Hamdani and Wolfgang A. Linke
Affiliation:
Keywords: Heart failure, β adrenergic receptors, myofilament proteins, cardiomyocytes
Abstract: Heart failure is characterized by elevated circulating catecholamine levels and extensive abnormalities in β-adrenergic receptor signaling. Under physiological conditions, sympathetic modulation via catecholamines induces positive inotropic, chronotropic and lusitropic responses. Well established in heart failure patients is a pronounced activation of the sympathetic system, accompanied by downregulation and desensitization of β-adrenergic receptors, leading to a markedly diminished β-adrenergic contractile response. In this review, we will discuss the normal β-adrenergic receptor signaling pathway in the heart and focus on the pathphysiological alterations of β-adrenergic receptor signaling and contractile proteins in heart failure.
Export Options
About this article
Cite this article as:
Hamdani Nazha and A. Linke Wolfgang, Alteration of the Beta-Adrenergic Signaling Pathway in Human Heart Failure, Current Pharmaceutical Biotechnology 2012; 13 (13) . https://dx.doi.org/10.2174/1389201011208062522
DOI https://dx.doi.org/10.2174/1389201011208062522 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Plasticity and Maintenance of Hematopoietic Stem Cells During Development
Recent Patents on Biotechnology Targeting Antibody-Mediated Rejection in the Setting of ABOIncompatible Infant Heart Transplantation: Graft Accommodation vs. B Cell Tolerance
Current Drug Targets - Cardiovascular & Hematological Disorders The Role of Dronedarone in the Treatment of Atrial Fibrillation/Flutter in the Aftermath of PALLAS
Current Cardiology Reviews Use of Angiotensin Receptor Blockers and Risk of Alzheimer’s Disease: A Class Effect?
Current Reviews in Clinical and Experimental Pharmacology Recent Advances in the Development of Multi-Kinase Inhibitors
Mini-Reviews in Medicinal Chemistry Intradialytic Hypertension: An Under-recognized Cardiovascular Risk Factor. What is the Evidence?
Current Hypertension Reviews Cytotoxic and Radio-sensitizing Effects of Polyphenolic Acetates in a Human Glioma Cell Line (BMG-1)
Current Pharmaceutical Design Statins in Aortic Stenosis
Current Pharmaceutical Design A Review of Type 2 Diabetes Mellitus Predisposing Genes
Current Diabetes Reviews Hepatocyte Growth Factor (HGF) for a Cell-Signal-Based Therapy During Acute and Chronic Liver Diseases
Current Signal Transduction Therapy Mucopolysaccharidosis Type IVA (Morquio A Disease): Clinical Review and Current Treatment: A Special Review
Current Pharmaceutical Biotechnology Recent Aspects of Osmotic Pump Systems: Functionalization, Clinical use and Advanced Imaging Technology
Current Drug Metabolism Micro-RNA in Disease and Gene Therapy
Current Drug Discovery Technologies Leptin and the Cardiovascular System: A Review
Recent Patents on Cardiovascular Drug Discovery Hypertension and Endothelial Dysfunction: Therapeutic Approach
Current Vascular Pharmacology Non Peptidic Urotensin II Antagonists: Perspectives for a New Class of Drugs
Cardiovascular & Hematological Agents in Medicinal Chemistry Perinatal Heart Programming: Long-term Consequences
Current Medicinal Chemistry Rheumatoid Arthritis and Cardiovascular Risk: Between Lights and Shadows
Current Rheumatology Reviews Ex Vivo and In Vivo Approaches to Study Mechanisms of Cardioprotection Targeting Ischemia/Reperfusion (I/R) Injury: Useful Techniques for Cardiovascular Drug Discovery
Current Drug Discovery Technologies Hyaluronan and Hyaluronan Synthases: Potential Therapeutic Targets in Cancer
Current Drug Targets - Cardiovascular & Hematological Disorders